Revenue, 2025

USD 1.3 Billion

Forecast, 2035

USD 2.61 Billion

CAGR, 2026-2035

7.2%

Report Coverage

United States

U.S. Sex Reassignment Hormone Therapy Market

The U.S. sex reassignment hormone therapy market size was estimated at USD 1.3 billion in 2025 and is predicted to increase from USD 1.39 billion in 2026 to approximately USD 2.61 billion by 2035, expanding at a CAGR of 7.2% from 2026 to 2035. The U.S. sex reassignment hormone therapy market is growing because this therapy improves both gender incongruence and dysphoria by permitting individuals to express their gender identity and supportive changes in primary and secondary sex physiognomies

Key Takeaways

• United States sex reassignment hormone therapy market to crossed USD 1.39 billion by 2026.
• Market projected at USD 2.61 billion by 2035.
• CAGR of 7.2% expected in between 2026 to 2035.
• By hormone type, the estrogen segment held 55% market share in 2025.
• By hormone type, the testosterone segment held the second-largest market share of 35% in 2025, and is expected to grow at the fastest CAGR of 8.5% during the forecast period.
• By gender category, the male-to-female (MTF) segment held the largest market share of 60% in 2025.
• By gender category, the female-to-male (FTM) segment held the second-largest U.S. sex reassignment hormone therapy market share of 40% in 2025, and is expected to grow at the fastest CAGR of 8.5% during the forecast period.
• By route of administration, the oral segment held the largest market share of 40% in 2025.
• By route of administration, the injectable segment held the second-largest market share of 35% in 2025, and is expected to grow at the fastest CAGR of 8.0% during the forecast period.
• By end user, the hospitals segment held the largest market share of 50% in 2025.
• By end user, the clinics segment held a notable market share of 35% in 2025, and is expected to grow at the fastest CAGR of 7.5% during the forecast period.

Market Overview: What is the U.S. Contraceptive?

The U.S. sex reassignment hormone therapy market is growing, as this type of gender-affirming hormone therapy alleviates distress associated with gender identity, lowers suicidal ideation, raises body positivity, and enhances well-being overall. It supports improving sexual function by lessening symptoms like low libido, vaginal dryness, and erectile dysfunction, which are related to hormonal imbalances. Hormone replacement therapy should be tailored to the person's particular requirements and healthcare history. Hormone replacement therapy should be tailored to the individual's specific needs and medical history. Sex hormone replacement therapy advantageous intervention for persons with hormonal imbalances, such as menopause-related symptoms, gender dysphoria, or various healthcare conditions.

How is AI governing the U.S. Sex Reassignment Hormone Therapy Market?

AI-driven technology has huge potential to transform hormone therapy and women's wellness by creating care more precise, tailored, and responsive. AI-based tools enable early intervention, which is significant in preventing long-term challenges from hormonal imbalances such as infertility, osteoporosis, and metabolic disorders. AI-based diagnostic platforms support healthcare professionals in identifying hormone imbalances more accurately by analysing multifaceted data sets, including lab outputs, genetic data, and wearable device inputs. AI-driven devices are increasingly integrated with wearable devices and biosensors.

Future Outlook & Trends in the U.S. Sex Reassignment Hormone Therapy Market 

Rise of Telehealth:

Telehealth providing gender-affirming care via secure computer-generated platforms, this type of healthcare is supporting making medical care more accessible, more contented, and less isolated for trans and non-binary people.

Technological Advancements:

Hormone therapy for transgender and gender-fluid individuals improves mental well-being and quality of life by closely aligning someone’s outer appearance with their gender identity.

Trans-Masculine Care:

Trans-inclusive healthcare training and ongoing education are significant to improving access to high-quality transition-associated care. It mainly focuses on optimizing testosterone therapy to attain masculinizing changes like increased muscle mass, facial hair, and voice deepening.

Key Indicators and Highlights

Segmentation Analysis

By Hormone Type Insights

Estrogen Segment Led the U.S. Sex Reassignment Hormone Therapy Market in 2025

The estrogen segment contributed the largest market share of 55% in the market, as Estrogen hormone therapy efficiently relieves menopause symptoms such as hot flashes and vaginal dryness, avoids osteoporosis, and enhances bone health of the bone.  It retains vaginal walls thick, lubricated, and elastic, lowering pain related to penetrative sex. Estrogen therapy lowers the risks of cardiac disease and mortality in women in their 50s, but significantly increases these risks for women in their 70s.

The testosterone segment held the second largest share of approximately 35%, expected to grow at the fastest CAGR of 8.5% of the U.S. sex reassignment hormone therapy market in 2025, as testosterone replacement therapy (TRT) increases strength, muscle mass, and physical function in hypogonadal men. It also provides slight advances to sexual and erectile function.

The anti-androgens segment held a notable share of 10% in the market in 2025, as many patients use them for various purposes, such as slowing prostate cancer and minimizing the masculinizing effects of certain hormones. Antiandrogen therapy blocks or lowers the effects of androgens in the body.

By Gender Category Insights

Male-to-Female (MTF) Segment Led the U.S. Sex Reassignment Hormone Therapy Market in 2025

The male-to-female (MTF) segment contributed the largest market share of 60% in 2025, as this transformation involves estrogen to induce feminine features and sometimes anti-androgens to block testosterone. It causes the development of breasts, softer skin texture, and redistribution of fat to the hips and thighs. This also reduces muscle mass. Facial and body hair growth decelerates.

The female-to-male (FTM) segment held the second largest share of 40%, expected to grow at the fastest CAGR of 8.5% of the U.S. sex reassignment hormone therapy market in 2025, as in this type of transformation, masculinizing hormone therapy includes taking the male hormone testosterone. It prevents menstrual cycles and depresses the ovaries' capability to make estrogen. This hormone therapy is done alone or along with masculinizing surgery.

By Route of Administration Insights

The Oral Segment held the Largest Share in the Market in 2025

The oral segment contributed the largest market share of 40% in 2025, as oral hormone replacement therapy (HRT) supports managing symptoms of menopause, such as vaginal dryness and hot flashes. Oral HRT is more affordable. Oral estrogen is highly efficient at enhancing cholesterol levels. It passes through the liver.

The injectable segment held the second largest share of 35% and is expected to grow at the fastest CAGR of 8.0% of the U.S. sex reassignment hormone therapy market in 2025, as injectable hormone therapy is a significant part of gender-affirming medical care, and it is related to increased quality of life for transgender and gender-diverse (TGD) individuals.

The transdermal segment held a notable share of 20% of the market in 2025, as transdermal HRT effectively manages symptoms of menopause and has a bone-sparing effect. Transdermal estradiol (estrogen) patches are a significant way for transgender, non-binary, and gender-fluid patients to take estrogen for gender-affirming or feminizing hormone treatment.

The sublingual segment held a notable share of 5% of the market in 2025, as sublingual estradiol provides several apparent advantages over combined oral estradiol and cyproterone acetate for gender-affirming hormone therapy of treatment-naive trans women.

By End User Insights

The Hospitals Segment held the Largest Share of the Market in 2025

The hospitals segment contributed the largest market share of 50% in 2025, as hormone therapy for transgender and gender-fluid individuals enhances mental well-being and quality of life. Gender-sustaining hormone management alleviates distress associated with gender identity, lowers suicidal ideation, and increases body positivity.

The clinics segment held the second largest share of 35% and is expected to grow at the fastest CAGR of 7.5% of the U.S. sex reassignment hormone therapy market in 2025.  Access to hormone replacement therapy (HRT) involves positively to the mental health and quality of life of transgender individuals. Clinical supervision is significant for lowering risks.

Whereas the home care segment held a notable share of approximately 10% in the market in 2025, as home care services remove barriers like geographical distance to particular clinics, transportation expenses, and long waiting times. Home care cuts the costs, enhances health results, and lowers hospital stays.

Supply Chain Analysis

R&D:

• Research and development (R&D) for U.S. sex reassignment hormone therapy involves new drug delivery systems, pharmacokinetic and pharmacodynamic modelling, new formulations and therapy optimization, clinical research and long-term safety research, and specialized diagnostic solutions.
• Key Players: Novartis AG and Eli Lilly

Manufacturing Processes:

• Manufacturing processes, including the manufacturing of feminizing hormones, production of masculinizing hormones, production of GnRH agonists, and quality control and supervisory standards.
• Key Players: ASCEND Therapeutics and Pfizer Inc.

Patient Services:

• Patient services in the U.S. sex reassignment hormone therapy include inclusive, multidisciplinary care, including mental health assessments, initial healthcare evaluations, and tailored hormone prescriptions.
• Key Players: Viatris Inc. and AbbVie Inc.

Latest Updates of Key Players in the U.S. Sex Reassignment Hormone Therapy Market

SWOT Analysis

Strengths

• Feminizing hormone therapy is applied to change the body's hormone levels. Those hormone variations trigger physical changes that support better alignment of the body with an individual's gender identity.
• Individuals experiencing gender reassignment find empowerment in self-discovery and authenticity, liberation, and a renewed sense of identity.

Weakness

• There are major risks related to hormone therapy; serious risks of untreated gender dysphoria, like depression and anxiety, increasing rates of self-harm, suicidal ideation, and reckless attempts.

Opportunities

• Hormone therapy for transgender and gender-fluid individuals enhances mental well-being and quality of life by more closely aligning someone’s outer appearance with their gender identity.
• Feminizing therapy increasingly uses transdermal patches or gels to reduce the challenges of blood clots related to oral pills.

Threat

• Estrogen-driven birth control rises challenges of developing blood clots by three to four times compared to women not using hormonal contraception.

Recent Developments in the U.S. Sex Reassignment Hormone Therapy Market

• In February 2026, the U.S. Food and Drug Administration approved drug labeling changes to six menopausal hormone therapy products, also called hormone replacement therapy (HRT), to clarify the challenges and considerations for these drugs.
• In December 2025, the U.S. Department of Health and Human Services (HHS) announced a series of proposed government actions to carry out President Trump’s Executive Order directing HHS to end the practice of sex-rejecting procedures on children that expose young people to irreparable challenges.

Segments Covered in the Report

By Hormone Type

• Estrogen
  • Oral Estrogen
  • Injectable Estrogen
  • Transdermal Estrogen
• Testosterone
  • Injectable Testosterone
  • Transdermal Testosterone
• Anti-androgens
  • Oral Anti-androgens
  • Injectable Anti-androgens

By Gender Category

• Male-to-Female (MTF)
• Female-to-Male (FTM)

By Route of Administration

• Oral
• Injectable

By Distribution Channel

• Hospitals
• Clinics
• Transdermal (Patch)
• Sublingual

By End User

• Hospitals
• Clinics
• Home Care
• Others